Atea Pharmaceuticals Inc Bemnifosbuvir Global Phase 3 Registrational Trial - Corporate Call Transcript
Good morning, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Conference Call. (Operator Instructions)
I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Please proceed.
Good morning, everyone. And welcome to Atea's Pharmaceutical Bemnifosbuvir Clinical Development Program Update Conference Call. Earlier this morning, we issued a press release, which describes our novel global Phase III clinical trial design for bemnifosbuvir.
You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at ir.ateapharma.com in the Events and Presentations section. With me today from Atea is Chief Executive Officer and Founder, Dr. Jean-Pierre Sommadossi; Chief Development Officer, Dr. Janet Hammond; Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran; and our Chief
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |